Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2008

View Archived Issues

Manhattan successfully completes pre-IND meetings with FDA for Altoderm and Altolyn

Recent patents impart new oncolytic agents

FDA extends review period by three months for additional indication for antibiotic Doribax

AlphaMed successfully expresses a humanized version of alpha 1- antitrypsin

Pharmion's shareholders approve USD 2.9 billion acquisition of company by Celgene

ProStrakan receives Swedish marketing authorization for Rapinyl in breakthrough cancer pain

Recent UCB and Pierre Fabre patents report new compounds for treating neurological disorders

Novel therapeutic agents for gastrointestinal disorders described in recent patent literature

Beneficial effect of beclomethasone seen in patients with GI graft-versus-host disease

Favorable impact on survival seen with Neuradiab in malignant glioma

7TM enters metabolic disorder drug discovery collaboration with Dr. Reddy's

Anesiva submits sNDA for Zingo for needle insertion pain in adults

GSK cervical cancer candidate vaccine demonstrates long-term protection

KaloBios initiates phase I/II trial of KB-002 in persistent asthma

Neuroprotective synergy seen with lithium and valproic acid in vitro

Evidence links 5-HT2A-mGluR2 complex to psychosis

Zeria and Astellas co-develop and co-market Z-338 for functional dyspepsia in Japan

Oxford Biomedica completes enrolment in phase III TRIST study of Trovax in renal cancer

Lilly terminates Air insulin program for type 1 and type 2 diabetes

BioCancell submits pre-IND application to FDA for phase I clinical trials of BC-819 in cancer

Positive results from clinical phase I study of PL-3994 in congestive heart failure

Progen begins global phase III study of PI-88 in post-resection liver cancer

Genitope suspends development of MyVax personalized immunotherapy

Bionomis begins dose-finding preclinical study of its anti-anxiety candidate BNC-210

Avant completes merger of wholly owned subsidiary Callisto into Celldex

Sareum initiates in-house drug discovery program targeting the fatty acid synthase enzyme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...